drugset / Trial / NCT00587873

Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)

NCT00587873

Phase 2 Completed 18 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with recurrent or resistant Hodgkin's disease (HD) treated with sequential administration of oral 6-Thioguanin (6-TG) after IV Methotrexate (MTX).

Timeline

Start
1994-03
Primary completion
2003-12
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 24 mg/m2 Intravenous
Subject Thioguanine Small molecule 300 mg/m2 Oral
Background Leucovorin Small molecule 5 mg Oral

Indications